Evidence

KPV peptide human studies

There are no published clinical trials of KPV. What the human-derived research does include (cells, skin, blood samples) and what it cannot show.

By the KPV Peptide editorial team · Last reviewed November 11, 2026 · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)

Short answer

There are no human studies of KPV. FDA’s July 2026 review searched PubMed, Embase and ClinicalTrials.gov and found no clinical studies, no pharmacokinetic data and no case reports of KPV given to people by any route [FDA briefing 2026].

Human-derived research is not human research

Several studies use human material without giving KPV to anyone. They show what KPV does to human cells or tissue in a dish, which is useful for mechanism but cannot show effects, safety or doses in a person:

Donated blood: cytokine output in stimulated blood samples [Catania 1998].
Excised skin: permeation through dermatomed human skin [Pawar 2017].
Human cell lines: intestinal, airway, skin, monocytic and liver lines [Dalmasso 2008][Land 2012][Elliott 2004][Sung 2025][Barcellini 2000][Lee 2026].

KPV studies using human cells, tissue or blood (no human administration)
Study	Model	What was measured	Limitations	Grade
Catania 1998 Peptides Systemic inflammation and fever models	Ex vivo Whole blood from people with HIV, stimulated with LPS	Measured IL-1 and TNF-alpha production in donated blood samples; melanocortins including the tripeptide reduced both concentration-dependently.	Ex vivo blood samples; no peptide was given to any person.	Evidence grade D
Barcellini 2000 J Leukoc Biol Systemic inflammation and fever models	In vitro Human promonocytic U1 cells; monocyte-derived macrophages	Measured HIV-1 p24 release and NF-kappaB activation in infected cells; KPV reduced viral expression and NF-kappaB activation.	Cell culture only.	Evidence grade D
Elliott 2004 J Invest Dermatol Skin and keratinocyte models	In vitro Human HaCaT and normal human keratinocytes	Measured cAMP and intracellular calcium; no cAMP rise was detected, while rapid calcium responses occurred only when the cAMP pathway was inhibited.	Signalling readouts only; no inflammatory endpoint.	Evidence grade D
Dalmasso 2008 Gastroenterology Intestinal inflammation models	Animal Caco2-BBE, HT29-Cl.19A and Jurkat cells; DSS and TNBS colitis models in mice	Measured PepT1-mediated uptake, NF-kappaB and MAP kinase activation, and colonic cytokine mRNA; nanomolar KPV reduced these readouts and the two chemically induced colitis models showed lower inflammation scores.	Chemically induced mouse models; cytokine and histology endpoints only.	Evidence grade C
Land 2012 Int J Physiol Pathophysiol Pharmacol Airway epithelium	In vitro Human bronchial epithelial cells 16HBE14o- (TNF-alpha, RSV)	Measured NF-kappaB reporter activity, MMP-9, IL-8 and eotaxin; KPV reduced them and the study linked this to inhibition of p65RelA nuclear import at the importin-alpha3 site.	Single immortalised cell line; single-author study.	Evidence grade D
Pawar 2017 J Pharm Sci Skin and keratinocyte models · Delivery and formulation	Ex vivo Dermatomed human skin (in vitro permeation)	Measured transdermal permeation; passive permeation was below the 0.01 ug/mL detection limit, microneedles gave 4.4 ug/cm2/h, and iontophoresis plus microneedles gave 35-fold more than microneedles alone.	Excised skin; no biological endpoint.	Evidence grade D
Sung 2025 Tissue Cell Skin and keratinocyte models	In vitro Human HaCaT keratinocytes and 3D skin model exposed to PM10	Measured viability, ROS, ERK/p38 activation, apoptosis proteins, caspase-1 and IL-1 beta after PM10 exposure; KPV-treated cultures showed lower ROS and IL-1 beta and higher viability.	Cell line and reconstructed tissue only.	Evidence grade D
Lee 2026 Cytotechnology Lipid and adipocyte models	In vitro Human HepG2 hepatocytes (oleic-acid lipid loading)	Measured lipid accumulation, FAS expression, ROS, ERK, AKT/mTORC1 and PPAR-gamma phosphorylation in oleic-acid-loaded HepG2 cells treated with KPV.	Single hepatoma cell line.	Evidence grade D

What human studies would need to answer

How much KPV reaches the blood after a given route, and how quickly it is cleared.
Whether it causes local or systemic adverse effects, including immune reactions.
Whether any measured biomarker effect translates into a clinical outcome.

Until such studies exist, KPV’s benefits, side effects and dosage in people remain unknown.

Frequently asked questions

Are there any KPV clinical trials?

No published clinical trial of KPV exists. FDA’s 2026 review searched PubMed, Embase and ClinicalTrials.gov and found no studies of KPV administered to humans.

Is KPV safe for humans?

This is unknown. Without human studies, neither safety nor tolerability has been measured. See the side-effects page for what FDA reviewed.

References

Catania A, Garofalo L, Cutuli M et al. (1998). Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides. PubMed 9700761 · doi:10.1016/s0196-9781(98)00055-2[Ex vivo, grade D]
Pawar K, Kolli CS, Rangari VK et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci. PubMed 28343991 · doi:10.1016/j.xphs.2017.03.017[Ex vivo, grade D]
Land SC (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. PubMed 22837805[In vitro, grade D]
Elliott RJ, Szabo M, Wagner MJ et al. (2004). alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. PubMed 15102092 · doi:10.1111/j.0022-202X.2004.22404.x[In vitro, grade D]
Sung J, Ju SY, Park S et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. PubMed 40073467 · doi:10.1016/j.tice.2025.102837[In vitro, grade D]
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177 · doi:10.1053/j.gastro.2007.10.026[Animal, grade C]
Barcellini W, Colombo G, La Maestra L et al. (2000). Alpha-melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. J Leukoc Biol. PubMed 11073109[In vitro, grade D]
Lee JY, Lee J, Jung WK et al. (2026). Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. PubMed 42064835 · doi:10.1007/s10616-026-00967-z[In vitro, grade D]
U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]